4d agoGuruFocusBULLISH 56Analyst
PRAX Reiterated by BTIG -- Price Target Maintained at $826
Praxis Precision Medicine (PRAX) Analyst Rating Update On October 03, 2023, BTIG reaffirmed its "Buy" rating for Praxis Precision Medicine (PRAX) and maintai
Archived explainer. For the current picture see today's PRAX page.
Why Is PRAXIS PRECISION MED (PRAX) Stock Up Today?
By the Top Tier Newswire AI Desk · November 10, 2026 at 12:03 AM ET · reviewed against 5 wire stories
PRAXIS PRECISION MED (PRAX) is up +20.03% in the latest session. Our newswire has captured 5 stories on PRAX across 5 sources in the last 36 hours, with AI sentiment reading mixed (avg 57/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Praxis Precision Medicines (PRAX) shares surged 20.03% to close at $332.97. The primary driver was the company’s third-quarter 2026 financial results, which included a non-GAAP EPS beat and a substantial cash reserve that extends operational runway into 2028.
What Happened
Praxis Precision Medicines reported third-quarter 2026 financial results via an SEC Form 8-K filed on November 9, 2026. The company posted a non-GAAP EPS of -$3.23, which beat the consensus estimate of -$3.66 by $0.40. Management highlighted that cash and investments totaled approximately $1.3 billion as of September 30, 2026, providing funding for operations into 2028. The company also provided updates on its pipeline, noting that FDA reviews are ongoing for relutrigine with a PDUFA target action date of December 27, 2026, and ulixacaltamide HCI with a target action date of January 29, 2027.
Following the release, BTIG reaffirmed its "Buy" rating and maintained a price target of $826. Raymond James reiterated its "Strong Buy" rating on the stock. Wedbush also adjusted its price target for the company.
What The Data Shows
The stock’s market capitalization stands at $7.8 billion. The company remains unprofitable with a trailing twelve-month EPS of -$12.86, though revenue has grown 365.0% over the same period. The stock carries a beta of 2.84 and has traded within a 52-week range of $159.74 to $392.70. In the eight sessions leading up to the move, the stock gained 7.8%, rising from $264.49 to $285.06. On November 9, 2026, the stock printed 34 fresh 52-week highs and 4 fresh 52-week lows.
Recent congressional disclosures show four buys and zero sells in the last 90 days, with the most recent filing on October 12, 2026. Representative Gilbert Ray Cisneros, Jr. disclosed purchases of $1,001 to $15,000 on September 29, 2026, and July 30, 2026.
What To Watch
Investors will monitor the FDA review processes for relutrigine and ulixacaltamide HCI, with target action dates set for late 2026 and early 2027, respectively.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
PRAX by the numbers
Last: $332.97Session: +20.03%7 sessions: +7.78%Coverage: 5 stories / 5 sourcesAI sentiment: 57/100 (mixed)Mkt cap: $7.8B52w: $159.74 to $392.70
The headlines behind the move
4d agoInvesting.com Analyst RatingsBULLISH 63Analyst
Raymond James reiterates Strong Buy on Praxis Precision Medicines stock
Raymond James reiterates Strong Buy on Praxis Precision Medicines stock
4d agoSeeking AlphaBULLISH 64Earnings
Praxis Precision Medicines Non-GAAP EPS of -$3.23 beats by $0.40
Praxis Precision Medicines tops Q3 EPS estimates and boosts cash to $1.3B, funding operations into 2028.
4d agoSEC 8-KNEUTRAL 50General
Praxis Precision Medicines, Inc. (PRAX) files 8-K
Filed: 2026-11-09 AccNo: 0001689548-26-000086 Size: 260 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
4d agoBusiness InsiderNEUTRAL 52Earnings
Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2026 Financial Results
FDA reviews of relutrigine, with PDUFA target action date of December 27, 2026, and ulixacaltamide HCI, with PDUFA target action date of January 29, 2027, are ongoing
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on PRAX: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier PRAX move explainers: 2026-11-10 · 2026-11-09 · 2026-08-17 · 2026-08-07 · 2026-08-06